Does Rallies show 13F holders for ACLX?

Yes. Rallies tracks hedge fund and 13F ownership data for ACLX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ACLX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ACLX. It does not provide personalized investment advice.

ACLX (Arcellx, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Arcellx, Inc. Common Stock (ACLX) is a publicly traded Healthcare sector company. As of May 21, 2026, ACLX trades at $115.07 with a market cap of $6.73B and a P/E ratio of -28.27. ACLX moved +0.03% today. Year to date, ACLX is +62.44%; over the trailing twelve months it is +80.62%. Its 52-week range spans $47.86 to $115.13. Analyst consensus is hold with an average price target of $112.45. Rallies surfaces ACLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ACLX stock?

Hedge funds tracked by Rallies that own ACLX include Pentwater Capital, Davidson Kempner, Soros Fund, Duquesne Family, and Fortress Investment. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Arcellx, Inc. Common Stock.

ACLX Key Metrics

Key financial metrics for ACLX
Metric	Value
Price	$115.07
Market Cap	$6.73B
P/E Ratio	-28.27
EPS	$-4.07
Dividend Yield	0.00%
52-Week High	$115.13
52-Week Low	$47.86
Volume	16.12M
Avg Volume	0
Revenue (TTM)	$22.29M
Net Income	$-228.93M
Gross Margin	0.00%

Top Hedge Funds Holding ACLX

Pentwater Capital holds 2.87M shares of ACLX, changed +0.00% as of Mar 31, 2026.
Davidson Kempner holds 559.64K shares of ACLX, changed +0.00% as of Mar 31, 2026.
Soros Fund holds 200.00K shares of ACLX, changed +0.00% as of Mar 31, 2026.
Duquesne Family holds 74.10K shares of ACLX, changed +0.00% as of Dec 31, 2024.
Fortress Investment holds 18.18K shares of ACLX, changed +0.00% as of Mar 31, 2026.

Latest ACLX News

Gilead’s $7.8B Arcellx Purchase Is Third Oncology Acquisition — Apr 7, 2026
Gilead to Acquire Arcellx for $7.8B, Securing CAR-T Therapy Rights — Mar 25, 2026
Gilead to acquire Arcellx for $115 per share plus $5 CVR, valuing at $7.8B — Mar 23, 2026
Arcellx Shareholder Suit Targets $115 Cash and $5 CVR Gilead Deal — Mar 19, 2026
Arcellx CFO Sells 11,219 Shares at $113.82 as P/E Dives to -29.5 — Feb 26, 2026

Recent ACLX Insider Trades

Elghandour Rami sold 89.92K (~$10.24M) on Feb 27, 2026.
Gilson Michelle sold 11.22K (~$1.28M) on Feb 25, 2026.
Gilson Michelle sold 2.88K (~$194.99K) on Feb 19, 2026.

ACLX Analyst Consensus

18 analysts cover ACLX: 0 strong buy, 7 buy, 11 hold, 0 sell, 0 strong sell. Consensus rating is hold. Average price target: $112.45.

Common questions about ACLX

Who owns ACLX stock?: Hedge funds tracked by Rallies that own ACLX include Pentwater Capital, Davidson Kempner, Soros Fund, Duquesne Family, and Fortress Investment. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Arcellx, Inc. Common Stock.
Does Rallies show 13F holders for ACLX?: Yes. Rallies tracks hedge fund and 13F ownership data for ACLX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ACLX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ACLX. It does not provide personalized investment advice.